Statin use and the risk of esophageal cancer: A population-based case-control study

Expert Opinion on Drug Safety

Volumn 12, Issue 3, 2013, Pages 293-298

  Chan, Te Fu ^a,b   Chiu, Hui Fen ^a   Wu, Chen Hsuan ^c   Lin, Chih Lung ^a,d   Yang, Chun Yuh ^d,e  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Case control study; Esophageal cancer; Pharmacoepidemiology; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CANCER RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; ESOPHAGUS CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; TAIWAN;

CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; ODDS RATIO; RISK; TAIWAN;

EID: 84876525094     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.778241     Document Type: Article

References (40)

1. Wong WW, Dimitroulakos J, Minden MD, et al. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apotosis. Leukemia 2002;16:508-19 (Pubitemid 34460459)
2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005;366:1267-78
3. Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997;278:313-21 (Pubitemid 27339660)
4. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996;275:55-60 (Pubitemid 26004257)
5. Goldstein MR, Mascitelli L, Pezzetta F. Do statin prevent or promote cancer Curr Oncol 2008;15:76-7
6. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623-30 (Pubitemid 35379733)
7. Keyomarsi K, Sandoval L, Band V, et al. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991;51:3602-9
8. Dimitroulakos J, Marhin WH, Tokunaga J, et al. Microarray and biochemical analysis of lovastatin-induced apotosis of squamous cell carcinoma. Neoplasia 2002;4:337-46 (Pubitemid 34755844)
9. Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 2008;103:825-37 (Pubitemid 351501115)
10. Hawk ET, Viner JL. Statins in esophageal cancer cell lines: promising lead Am J Gastroenterol 2008;103:838-41 (Pubitemid 351501098)
11. Konturek PC, Burnat G, Hahn EG. Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins. J Physiol Pharmacol 2007;58(Suppl 3):141-8 (Pubitemid 47523111)
12. Park HJ, Hong D, Iruela-Arispe L, et al. 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002;91:143-50 (Pubitemid 34827225)
13. Weis M, Heeschen C, Glassford AJ, et al. Statins have biphasic effects on angiogenesis. Circulation 2002;105:739-45 (Pubitemid 34157379)
14. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer 2011;11:409
15. Friedman GD, Flick D, Udaltsova N, et al. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008;17:27-36 (Pubitemid 351166615)
16. Kaye JA, Jick H. Statin use and cancer risk in the general practice research database. Br J Cancer 2004;90:635-7 (Pubitemid 38297203)
17. Nguyen DM, El-Serag HB, Henderson L, et al. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2009;7:1299-304
18. Nguyen DM, Richardson P, El-Serag HB. Medications (NSAID, Statins, PPI) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 2010;138:2260-6
19. Kastelein F, Spaander MC, Biermann K, et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology 2011;141:2000-8
20. Kantor ED, Onstad L, Blount PL, et al. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2012;21:456-61
21. Chiang CW, Chen CY, Chiu HF, et al. Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003. Pharmacoepidemiol Drug Saf 2007;16:412-21
22. Kuo HW, Tsai SS, Tiao MM, et al. Epidemiologic features of CKD in Taiwan. Am J Kidney Dis 2007;49:46-55
23. Coogan P, Rosenberg L, Palmer JR, et al. Statin use and the risk of breast and prostate cancer. Epidemiology 2002;13:262-7 (Pubitemid 34415845)
24. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology 2007;18:213-19
25. Jadhav SB, Jain GK. Statins and osteoporosis: new role for old drugs. J Pharm Pharmacol 2006;58:3-18 (Pubitemid 43041991)
26. Meier CR, Scheinger RG, Kraenzlin ME, et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3205-10 (Pubitemid 30422037)
27. Rejnmark L, Plsen ML, Johnsen SP, et al. Hip fracture risk in statin users-a population-based Danish case-control study. Osteoporos Int 2004;15:452-8 (Pubitemid 38843173)
28. Wang PS, Solomon DH, Mogun H, et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3211-16 (Pubitemid 30422038)
29. WHO Collaborating Center for Drugs Statistics Methodology. ATC Index with DDDs 2003. WHO, Oslo; 2003
30. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005;114:643-7 (Pubitemid 40349625)
31. Goldstein MR, Mascitelli L, Pezzetta F. The doubleedged sword of statin immunomodulation. Int J Cardiol 2009;135:128-30
32. Mausner-Fainberg K, Luboshits G, Mor A, et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD+4CD+25 T cells. Atherosclerosis 2008;197:829-39 (Pubitemid 351417882)
33. Raemer PC, Kohl K, Watzl C. Statins inhibit NK-cell cytotoxicity by interfering with LFA-1-mediated conjugate formation. Eur J Immunol 2009;39:1456-65
34. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7
35. Blanco-Colio LM, Villa A, Ortego M, et al. 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apotosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002;161:17-26 (Pubitemid 34214817)
36. Danesh FR, Sadeghi MM, Amro N, et al. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci USA 2002;99:8301-5 (Pubitemid 34651047)
37. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-19 (Pubitemid 34219772)
38. Shibata MA, Avanaugh C, Shibata E, et al. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 2003;24:453-9 (Pubitemid 36432640)
39. Rao S, Porter DC, Chen X, et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 1999;96:7797-802 (Pubitemid 29328361)
40. Kuo HW, Tsai SS, Tiao MM, et al. Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf 2010;19:745-51